CRAMSN COO: Strategic CDMO Model Requires Separate Operating Teams, Not One-Size-Fits-All Approach
- CRAMSN's Mathad argues CDMOs must shift from transactional service delivery to strategic ownership, with distinct operating models for biotech versus large pharma clients.
- Supply chain resilience demands backward integration of chemistry and vendor diversification across 18 manufacturing plants, designed at program start rather than bolted on during crises.
- Sustainability performance hinges on three levers: raw material transportation, process chemistry optimization (PMI, green solvents), and renewable energy sourcing across manufacturing operations.
Operational Impact
CRAMSN's 18-plant network and regional manufacturing strategy signal a structural shift toward geographic diversification and backward chemistry integration that may influence how biotech and pharma clients evaluate CDMO resilience and sustainability credentials.
Source: PharmaSource RSS